How Psilocybin Rewires the Brain: The Science Behind Neural Transformation

Whether faced with depression, post-traumatic stress disorder, or serious physical trauma, the human brain has proved remarkably resilient in its ability to recover and rebound. This ability to recover is in large part thanks to neuroplasticity: the brain’s ability to adapt by forming new neural connections, reorganizing existing pathways, and recalibrating to new experiences. Neuroplasticity acts as the backbone behind a wealth of processes: learning, memory formation, and recovery from neurological conditions.

‍

Due to its promising ability to enable and enhance these very same processes, psilocybin has gained significant scientific and therapeutic attention. While these naturally-occurring psychedelic mushrooms have found long-standing use for their mind-altering properties, contemporary research now pivots toward psilocybin's potential therapeutic applications, particularly for mental health conditions.

‍

This article examines the evidence suggesting that psilocybin may temporarily increase neuroplasticity, creating a landscape that allows for significant, long-term improvements in mental health and overall wellbeing.

‍

How Psilocybin Interacts with the Brain: Unlocking Neural Pathways

When consumed, psilocybin undergoes metabolic conversion in the body to its active form, psilocin. This compound primarily acts by binding to serotonin receptors in the brain, with particular affinity for the 5-HT2A receptor subtype found predominantly in cortical regions.

‍

The activation of these 5-HT2A receptors triggers multiple intracellular signaling pathways critical for neuroplasticity. Key among these are:

• Brain-Derived Neurotrophic Factor (BDNF) pathway: This supports neuron survival, growth, and differentiation, playing vital roles in both neurogenesis (creating new neurons) and synaptogenesis (forming new connections between neurons).
• Mammalian target of rapamycin (mTOR) pathway: Critical for synaptic plasticity, this pathway influences protein synthesis necessary for structural changes underlying learning and memory.

‍

Recent findings suggest that psilocin’s activation of 5-HT2A receptors elevates extracellular glutamate levels in the brain. This increase in glutamate stimulates AMPA receptors: ionotropic glutamate receptors that mediate fast synaptic transmission and are essential for learning and memory. AMPA receptor activation, in turn, promotes the release of brain-derived neurotrophic factor (BDNF), which binds to TrkB receptors and initiates mTOR signaling. This cascade forms a reinforcing loop: mTOR activity and continued AMPA engagement both contribute to further BDNF expression. Together, these mechanisms support the dendritic growth and synaptic remodeling observed after psilocybin use, encouraging improved emotional flexibility, cognitive function, and neuroplasticity.

‍

Psilocybin also significantly influences the default mode network (DMN), a network of brain regions active during introspection, mind-wandering, and self-referential processing. Research indicates that psilocybin can temporarily disrupt typical DMN activity and connectivity, potentially weakening rigid thought and behavior patterns and creating opportunities for new perspectives to emerge.

‍

Beyond these direct effects, psilocybin may enhance the brain's overall capacity for change 

through "metaplasticity," the ability of neural networks to modify their own plasticity. In essence, this adaptability primes the brain to become more responsive to new experiences and learning.

‍

Evidence for Psilocybin-Induced Neuroplasticity: The Science of Rewiring

Growing research provides compelling evidence for psilocybin's ability to promote neuroplastic changes in the brain:

• Gene expression changes: Studies in rats show that psilocybin upregulates genes associated with neuroplasticity within 1.5 hours of administration, particularly in the prefrontal cortex. These molecular responses represent some of the earliest signs of enhanced neuroplasticity following psilocybin exposure.
• Synaptogenesis: Psilocybin encourages the formation of new connections between neurons. In a study using pigs, a single hallucinogenic dose of psilocybin was found to increase presynaptic density in both the prefrontal cortex and hippocampus.
• Enhanced dendritic spine density: Research demonstrates that psilocybin increases the density and complexity of dendritic spines—small protrusions on nerve cells crucial for information transmission between neurons. One study using chronic two-photon microscopy in mice revealed that a single psilocybin dose led to approximately a 10% increase in both size and density of dendritic spines in the medial frontal cortex within 24 hours, with changes persisting for at least one month.
• Increased functional connectivity: Psilocybin enhances communication between different brain regions, fostering a more flexible brain state that may help individuals break free from entrenched rumination patterns often seen in conditions such as severe and treatment-resistant depression.

‍

Remarkably, these changes in brain connectivity and structure have been observed weeks after psilocybin's acute effects have subsided, suggesting that its initial action triggers longer-term neuroplastic processes rather than just producing temporary alterations. In mice, for instance, while the enhanced rate of dendritic spine formation returned to baseline within 5 days after psilocybin administration, the new dendrites formed during this period survived for at least one month afterward. 

‍

While still largely experimental, these findings may demonstrate that structural changes induced by psilocybin can outlast the actual window of enhanced plasticity. This would mean that even after the neuroplasticity window has closed, newly-molded neurological changes remain. 

‍

Regional Specificity: Where in the Brain Does Psilocybin Work?

Psilocybin's effects on neuroplasticity vary across different brain regions, with the most pronounced impacts occurring in areas with high 5-HT2A receptor expression:

• Neocortex: The neocortex, particularly the prefrontal cortex (PFC), shows the most robust neuroplastic response to psilocybin. Studies have demonstrated rapid upregulation of plasticity-related genes in the PFC, increased presynaptic density, and enhanced dendritic spine formation in this region. Depression and anxiety disorders are characterized by reduced cortical neuroplasticity and synaptic atrophy in the PFC, compromising its ability to regulate limbic regions.
• Hippocampus: While psilocybin upregulates fewer plasticity-related transcripts in the hippocampus compared to the cortex, it still produces significant effects. Pigs exposed to psilocybin showed increased presynaptic density in the hippocampus, and psilocybin strengthens cortico-hippocampal synapses. The relatively reduced neuroplastic effects in the hippocampus might be explained by its greater density of 5-HT1A compared to 5-HT2A receptors.
• Other regions: Preliminary evidence suggests psilocybin may enhance neuroplasticity in other brain areas including the claustrum, locus ceruleus, and certain regions of the thalamus and amygdala, though these effects are generally less documented than cortical changes.

‍

Given psilocybin’s pronounced effects in critical regions for emotional regulation and cognitive flexibility, this local specificity may help explain its particular potential in treating mood disorders, 

‍

The Timing of Neuroplasticity: A Critical Window

Understanding when psilocybin opens a "window of plasticity" and how long this window remains open is crucial for optimizing therapeutic applications. Current evidence suggests the following timeline:

• Initial changes (1-5 hours): The earliest neuroplastic changes begin within 1-6 hours after psilocybin administration, with alterations in gene expression appearing first. Upregulation of neuroplasticity-related transcripts can occur within just one hour.
• Cellular changes (6-23 hours): Changes in cellular morphology, including dendritic growth and synaptogenesis, become evident starting around 7 hours post-administration, with effects often continuing to increase at 24 hours.
• Peak effects (24-72 hours): Some studies suggest that the rate of dendritic spine formation peaks between 24-72 hours after psilocybin exposure.
• Window closure (approximately 5 days): In mice, the enhanced rate of dendritic spine formation returns to baseline around 5 days after psilocybin administration.
• Persistence of structural changes (1+ months): Crucially, while the enhanced rate of new dendrite formation subsides within days, the new dendrites and synapses formed during this window can persist for one month, and potentially longer.

‍

This timeline has important implications for therapeutic approaches. The fact that the neuroplasticity window overlaps with psilocybin's subjective effects suggests that experiences during the psychedelic state may have enhanced potential to reshape neural circuitry. Additionally, the persistence of structural changes long after the drug has been metabolized explains how psilocybin can produce benefits lasting for months after a single dose.

‍

Read more: Psilocybin Mushrooms: Onset Time, Duration, and How Long They Stay in Your System 

‍

Experience-Dependent Neuroplasticity: The Importance of Context

Neuroplastic changes occur in an experience-dependent manner. This is particularly relevant for psilocybin therapy because the window of enhanced plasticity overlaps with the drug's subjective effects. However, due to the uncertainty involved, this creates both opportunities and challenges:

• Therapeutic opportunities: In safe, supportive environments, psilocybin can catalyze personally meaningful, emotionally salient experiences that may lead to lasting positive changes. Patients often report insights into personal problems, emotional breakthroughs, reprocessing of traumatic memories, and feelings of connectedness. Research has found that mystical experiences, emotional breakthroughs, and insights during psilocybin sessions correlate significantly with positive long-term outcomes, independent of the overall intensity of drug effects. 
• Risk considerations: Challenging experiences during psilocybin administration, particularly prolonged distressing experiences, could potentially lead to undesirable neuroplastic changes. However, with proper screening, preparation, and therapeutic support, challenging experiences often constitute a crucial part of psychological growth. 
• Synergy with psychotherapy: Enhanced neuroplasticity may make individuals more responsive to concurrent therapeutic interventions. This suggests that combining psilocybin with appropriate psychotherapy could generate effects greater than either approach alone—a principle that guides current models of psilocybin-assisted therapy.

‍

Therapeutic Applications: Remodeling the Brain for Better Mental Health

Psilocybin's neuroplasticity-enhancing properties have spurred significant research into its therapeutic potential for various mental health conditions:

‍

Depression

Research has focused extensively on psilocybin-assisted psychotherapy for depression, including treatment-resistant cases where conventional antidepressants have failed. Studies suggest significant and lasting reductions in depressive symptoms following psilocybin therapy. The proposed mechanism involves psilocybin's ability to increase brain flexibility and disrupt rigid, negative thought patterns characteristic of depression.

‍

By enhancing neuroplasticity in the PFC, psilocybin may help restore the brain's regulatory capabilities. Studies show depressed patients treated with psilocybin exhibit increased connectivity between the PFC and limbic regions, with these changes occurring alongside decreases in negative affect and anxiety.

‍

Anxiety

Studies have explored psilocybin-assisted treatment for anxiety, including existential distress often experienced by individuals with serious or terminal illnesses. Research indicates that psilocybin-assisted therapy can lead to substantial improvements in anxiety symptoms, sometimes lasting for several months after treatment.

Anxiety disorders, including PTSD and social anxiety, are associated with fewer synaptic connections between the medial PFC and the amygdala, compromising the PFC's ability to regulate fear responses. Psilocybin's enhancement of cortical neuroplasticity may help strengthen these connections, improving top-down control over anxiety reactions.

‍

Post-Traumatic Stress Disorder (PTSD)

Preliminary findings suggest psilocybin's promise for treating PTSD. Animal studies indicate that psilocybin can promote fear extinction—a process often impaired in PTSD—and may increase neuroplasticity in the hippocampus, a region crucial for memory and emotional processing.

‍

Addiction

Research has investigated psilocybin-assisted therapy for addressing substance use disorders, including alcohol and tobacco addiction. Severe addiction has the capacity to impair neuroplasticity in the circuits between the PFC and reward-related brain regions. As such, psilocybin’s restorative properties may help repair the brain’s ability to regulate addictive impulses and behaviors. 

‍

Furthermore, some studies show that psilocybin can help reduce cravings and promote long-term abstinence, suggesting that its influence on neuroplasticity might facilitate breaking habitual behaviors associated with addiction.

‍

Safety Considerations, Risks, and Legal Status

‍

Safety and Risks

In controlled, supervised settings, psilocybin generally demonstrates a favorable safety profile, with serious adverse events being rare. However, individuals may experience short-term side effects including:

• Altered perception
• Increased heart rate and blood pressure
• Nausea
• Anxiety
• Paranoia

‍

Unsupervised and unprepared journey goers are generally more susceptible to the dreaded "bad trip," characterized by intense fear, anxiety, or distress. However, if navigated correctly with the help of expert facilitators, these experiences can be conducive to psychological transformation. 

‍

Contraindications

Certain individuals should avoid psilocybin use, including those with:

• Personal or family history of psychotic disorders
• Severe cardiovascular issues
• Severe hypertension
• Acute infectious diseases
• Epilepsy or seizures

‍

Additionally, psilocybin may interact with certain medications, particularly those affecting the serotonergic system, and should not be taken concurrently with substances like cocaine, amphetamines, MDMA, and certain other psychedelics.

‍

Legal Status

Psilocybin remains classified as a Schedule I controlled substance under U.S. federal law, indicating a high potential for abuse and no accepted medical use. However, several states and municipalities have enacted measures to decriminalize or regulate its use for therapeutic purposes:

• Oregon: Pioneered the legalization of psilocybin for supervised personal use through Measure 109, with licensed service centers now operational.
• Colorado: Passed Proposition 122, legalizing psilocybin for limited personal use and initiating the development of a regulated therapeutic framework.
• New Mexico: In April 2025, enacted the Medical Psilocybin Act (SB 219), becoming the third state to legalize psilocybin and the first to do so via legislative action. The law permits patients with qualifying conditions—such as treatment-resistant depression, PTSD, substance use disorders, and end-of-life anxiety—to access psilocybin therapy under the supervision of licensed clinicians in approved settings. The program is tentatively slated for implementation by December 31, 2027.

‍

Current Research Limitations and Future Directions

While psilocybin has encountered resistance due to outdated perceptions of psychedelic potential, current limitations in research are a key factor as well. While findings regarding psilocybin's impact on brain rewiring and therapeutic potential are encouraging, several caveats must be acknowledged:

• Many studies have relatively small sample sizes
• Blinding participants in clinical trials involving psychoactive substances presents significant challenges
• More research is required to understand the long-term effects of psilocybin therapy
• Optimal dosing protocols remain somewhat unclear, with more work needed to determine minimum and optimal doses for stimulating neuroplasticity
• Further research is needed to establish causal links between neuroplastic changes and therapeutic outcomes

‍

Ongoing debates within the scientific community persist regarding optimal protocols for psilocybin therapy, the relative importance of pharmacological effects versus psychological support, and the precise neurobiological mechanisms underlying therapeutic actions.

Future research will likely focus on addressing these limitations and exploring new avenues, including:

• Investigating the long-term durability of psilocybin's therapeutic effects
• Identifying biomarkers that can predict individual responses to treatment
• Exploring psilocybin's potential for treating a wider range of conditions, including opioid addiction, Alzheimer's disease, and anorexia nervosa
• Developing more effective methods to measure neuroplasticity in humans, such as protocols that induce LTP-like changes or PET studies with markers of synaptic density
• Understanding the potential of non-hallucinogenic "microdoses" to enhance neuroplasticity, which could have applications for conditions like stroke, brain injury, and neurodegenerative disorders

‍

Conclusion: The Promise of Neural Transformation Through Psilocybin

Altogether, current evidence strongly suggests that psilocybin possesses the remarkable ability to potentially rewire the brain through various neuroplastic mechanisms. By interacting with serotonin receptors and influencing key signaling pathways, psilocybin enhances synaptic connections, increases dendritic spine density, and fosters greater connectivity between brain regions. These changes can lead to a more flexible brain state capable of breaking free from maladaptive thought and behavior patterns.

‍

The therapeutic implications of these neuroplastic effects are significant. Psilocybin-assisted therapy is emerging as a promising approach for treating various mental health conditions, offering hope to individuals who haven't found relief with traditional treatments.

‍

While psilocybin's safety profile in controlled settings appears favorable, acknowledging potential risks and contraindications remains essential. Furthermore, the legal landscape continues to evolve under intense focus and scrutiny. As such, ongoing research is more crucial than ever in order to realize psilocybin's therapeutic potential while maintaining safe and responsible use. Psilocybin's capacity for neurological rewiring presents a potential transformation in how we approach mental health.

‍

Frequently Asked Questions (FAQs)

How does psilocybin change the brain? Psilocybin promotes neuroplasticity by stimulating growth of dendritic spines, enhancing neural connections, and increasing communication between brain regions.

Is psilocybin therapy legal? Psilocybin-assisted therapy is illegal on a federal level. Certain states, such as Oregon, Colorado, and New Mexico, have legalized or decriminalized regulated psilocybin use.

How long do psilocybin's effects on the brain last? Research shows neuroplastic changes can persist for weeks or months after administration, long after acute psychedelic effects subside.

What mental health conditions might benefit from psilocybin therapy? Current research shows promise for depression, anxiety, PTSD, and substance use disorders.

Is psilocybin therapy safe? In controlled clinical settings with proper screening, psilocybin generally shows a favorable safety profile, though caution is advised in unsupervised settings.

How does psilocybin affect the default mode network? Psilocybin temporarily disrupts the DMN's typical activity patterns, potentially breaking rigid thought patterns and enabling new perspectives.

Can psilocybin help with treatment-resistant depression? Multiple studies suggest psilocybin therapy may benefit individuals with depression who haven't responded to conventional treatments.

Who should avoid taking psilocybin? People with a family history of psychosis, severe cardiovascular issues, epilepsy, or taking certain medications should avoid psilocybin therapy.

What is neuroplasticity and why is it important? Neuroplasticity is the brain's ability to adapt by forming new neural connections, essential for learning, recovery, and adapting to new experiences.

How is psilocybin therapy typically administered? Therapeutic protocols typically involve preparation sessions, supervised administration in a controlled setting, and integration sessions to process the experience.

‍

Key Citations

"Are Magic Mushrooms Legal in California?" The Nieves Law Firm, https://thenieveslawfirm.com/are-magic-mushrooms-legal-in-california/. Accessed 10 May 2025.

"Are Magic Mushrooms Legal in California?" WeCann, 19 Apr. 2024, https://www.wecannca.com/psychedelics-psilocybin-licensing-updates/. Accessed 10 May 2025.

"Are Psychedelics Dangerous? Risks, Considerations, Contraindications." Verywell Mind, 28 Apr. 2024, https://www.verywellmind.com/are-psychedelics-dangerous-risks-considerations-contraindications-6742167. Accessed 10 May 2025.

"California Psilocybin Mushroom Legalization Initiative (2024)." Ballotpedia, https://ballotpedia.org/California_Psilocybin_Mushroom_Legalization_Initiative_(2024. Accessed 10 May 2025.

"California 2025 Legislative Update." Manzuri Law, 17 Apr. 2025, https://manzurilaw.com/california-2025-legislative-update/. Accessed 10 May 2025.

"Clinical Trials Using Psilocybine." National Cancer Institute, https://www.cancer.gov/research/participate/clinical-trials/intervention/psilocybine. Accessed 10 May 2025.

"COMP360 in Participants With TRD." UC San Diego Health, https://clinicaltrials.ucsd.edu/psilocybin. Accessed 10 May 2025.

Daws, Richard E., et al. "Psilocybin for anxiety and depression in patients with cancer: a systematic review and meta-analysis." Journal of Clinical Oncology, vol. 40, no. 34, 2022, pp. 3965-78.

"Decriminalize California." Decriminalize California, https://www.decriminalizeca.org/. Accessed 10 May 2025.

"How Psilocybin Can Rewire Our Brain, Its Therapeutic Benefits & Its Risks - Huberman Lab." Huberman Lab, 8 May 2023, https://www.hubermanlab.com/episode/how-psilocybin-can-rewire-our-brain-its-therapeutic-benefits-and-its-risks. Accessed 10 May 2025.

"How Psychedelic Drugs Alter Brain." National Institutes of Health (NIH), 18 July 2024, https://www.nih.gov/news-events/nih-research-matters/how-psychedelic-drugs-alter-brain. Accessed 10 May 2025.

"Legal Status of Psilocybin Mushrooms." Wikipedia, 7 May 2025, https://en.wikipedia.org/wiki/Legal_status_of_psilocybin_mushrooms. Accessed 10 May 2025.

Madsen, Kasper R., et al. "Psilocybin desynchronizes the human brain." Nature, vol. 632, no. 8023, 2024, pp. 600-06.

"Magic Mushrooms." Canada.ca, 29 Feb. 2024, https://www.canada.ca/en/health-canada/services/substance-use/controlled-illegal-drugs/magic-mushrooms.html. Accessed 10 May 2025.

"Magic Mushrooms Effectively Decriminalized In Oakland." NPR, 5 June 2019, https://www.npr.org/2019/06/05/730061916/oakland-city-council-effectively-decriminalizes-psychedelic-mushrooms. Accessed 10 May 2025.

"Magic mushroom compound increases brain connectivity in people with depression." Imperial College London, 11 Apr. 2022, https://www.imperial.ac.uk/news/235514/magic-mushroom-compound-increases-brain-connectivity/. Accessed 10 May 2025.

"Magic mushrooms temporarily 'dissolve' brain network responsible for sense of self." Live Science, 17 July 2024, https://www.livescience.com/health/neuroscience/magic-mushrooms-temporarily-dissolve-brain-network-responsible-for-sense-of-self. Accessed 10 May 2025.

"Medical Uses and Adverse Effects of Psilocybin." Psychiatrist.com, 25 Apr. 2023, https://www.psychiatrist.com/pcc/medical-uses-adverse-effects-psilocybin/. Accessed 10 May 2025.

"New Mexico Becomes Third State in the U.S. to Legalize Access to Psilocybin." Foley & Lardner LLP, 9 Apr. 2025, https://www.foley.com/insights/publications/2025/04/new-mexico-becomes-third-state-us-legalize-access-psilocybin/. Accessed 10 May 2025.

"Oakland City Council Decriminalizes Psychedelic Mushrooms." Filter, 13 June 2019, https://filtermag.org/oakland-psychedelic-decriminalization-impact/. Accessed 10 May 2025.

Osorio, Lolita. "Psilocybin 'Rewires' the Brain to Alleviate Depression." Medscape, 11 Apr. 2022, https://www.medscape.com/viewarticle/971965. Accessed 10 May 2025.

"Psilocybin." Wikipedia, 7 May 2025, https://en.wikipedia.org/wiki/Psilocybin. Accessed 10 May 2025.

"Psilocybin and Neuroplasticity: A Review of Preclinical and Clinical Studies." Open Foundation, 2024, https://open-foundation.org/psilocybin-and-neuroplasticity/. Accessed 10 May 2025.

"Psilocybin and the Default Mode Network." Synthesis Retreat, 18 Apr. 2023, https://www.synthesisretreat.com/psilocybin-and-the-default-mode-network. Accessed 10 May 2025.

"Psilocybin clinical trial for Alcohol Use Disorder & PTSD: PsiloStudy." University of Washington, 18 Mar. 2025, https://ntap.psychiatry.uw.edu/psilostudy/. Accessed 10 May 2025.

"Psilocybin for Anxiety." GoodRx, 21 Aug. 2023, https://www.goodrx.com/conditions/generalized-anxiety-disorder/psilocybin-for-anxiety. Accessed 10 May 2025.

"Psilocybin for Mental Health and Addiction: What You Need To Know." National Center for Complementary and Integrative Health, U.S. Department of Health and Human Services, https://www.nccih.nih.gov/health/psilocybin-for-mental-health-and-addiction-what-you-need-to-know. Accessed 10 May 2025.

"Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo." PubMed Central (PMC), 11 July 2021, https://pmc.ncbi.nlm.nih.gov/articles/PMC8376772/. Accessed 10 May 2025.

"Psilocybin is a Schedule 1 Controlled Substance." U.S. Department of Justice Drug Enforcement Administration, https://www.dea.gov/sites/default/files/2020-06/Psilocybin-2020.pdf. Accessed 10 May 2025.

"Psilocybin Legal Status." Recovered.org, 19 Dec. 2024, https://recovered.org/hallucinogens/psilocybin/psilocybin-legal-status. Accessed 10 May 2025.

"Psilocybin May Offer Fast and Lasting Antidepressant Benefits by Enhancing Brain Plasticity." PsyPost, 2 Apr. 2025, https://www.psypost.org/psilocybin-may-offer-fast-and-lasting-antidepressant-benefits-by-enhancing-brain-plasticity/. Accessed 10 May 2025.

"Psilocybin rewires brain in people with depression." University of California San Francisco, 11 Apr. 2022, https://www.ucsf.edu/news/2022/04/422606/psilocybin-rewires-brain-people-depression. Accessed 10 May 2025.

"Psilocybin Safety." Cancer Choices, 19 Mar. 2024, https://cancerchoices.org/therapy/psilocybin/safety/. Accessed 10 May 2025.

"Psilocybin spurs growth of neural connections lost in depression." YaleNews, 5 July 2021, https://news.yale.edu/2021/07/05/psychedelic-spurs-growth-neural-connections-lost-depression. Accessed 10 May 2025.

"Psilocybin Therapy for Chronic Low Back Pain." UCSF Clinical Trials, https://clinicaltrials.ucsf.edu/psilocybin. Accessed 10 May 2025.

"Psilocybin Therapy for PTSD and Depression." Cannabis Science and Technology, 8 June 2022, https://www.cannabissciencetech.com/view/psilocybin-therapy-for-ptsd-and-depression. Accessed 10 May 2025.

"Psilocybin Treatment for Major Depression Effective for Up to a Year for Most Patients, Study Shows." Johns Hopkins Medicine, 15 Feb. 2022, https://www.hopkinsmedicine.org/news/newsroom/news-releases/2022/02/psilocybin-treatment-for-major-depression-effective-for-up-to-a-year-for-most-patients-study-shows. Accessed 10 May 2025.

"Psilocybin-induced default mode network hypoconnectivity is blunted in alcohol-dependent rats." PsyPost, 2 Apr. 2025, https://www.psypost.org/new-neuroimaging-findings-pave-the-way-for-key-insights-into-psychedelic-therapy/. Accessed 10 May 2025.

"Psychedelic Drug Therapy May Address Mental Health Concerns in People With Cancer & Addiction." NYU Langone Health, 2 Jan. 2025, https://nyulangone.org/news/psychedelic-drug-therapy-may-address-mental-health-concerns-people-cancer-addiction. Accessed 10 May 2025.

"Psychedelic spurs growth of neural connections lost in depression." YaleNews, 5 July 2021, https://news.yale.edu/2021/07/05/psychedelic-spurs-growth-neural-connections-lost-depression. Accessed 10 May 2025.

"Psychedelics and Neural Plasticity: Therapeutic Implications." PubMed Central (PMC), 18 Nov. 2022, https://pmc.ncbi.nlm.nih.gov/articles/PMC9665925/. Accessed 10 May 2025.

"Psychedelics can reopen periods of heightened brain plasticity." BrainFacts.org, 15 May 2024, https://www.brainfacts.org/thinking-sensing-and-behaving/brain-development/2024/psychedelics-can-reopen-periods-of-heightened-brain-plasticity--051524. Accessed 10 May 2025.

"Psychedelics Research." Johns Hopkins Medicine, https://www.hopkinsmedicine.org/psychiatry/research/psychedelics-research. Accessed 10 May 2025.

"Psychedelics: The State of the Science." Harvard Medicine, 2021, https://magazine.hms.harvard.edu/articles/altering-perceptions-psychedelics. Accessed 10 May 2025.

"Study Suggests New Mechanism for How Psychedelics Affect the Brain." University of California San Francisco, 11 Apr. 2022, https://www.ucsf.edu/news/2022/04/422606/psilocybin-rewires-brain-people-depression. Accessed 10 May 2025.

"The emergence of psychedelics as medicine." American Psychological Association, June 2024, https://www.apa.org/monitor/2024/06/psychedelics-as-medicine. Accessed 10 May 2025.

"The Intersection of Psychedelics and Neuroplasticity: Rethinking Therapeutic Approaches for Mental Health." Herald Scholarly Open Access, 19 Dec. 2023, https://www.heraldopenaccess.us/openaccess/the-intersection-of-psychedelics-and-neuroplasticity-rethinking-therapeutic-approaches-for-mental-health. Accessed 10 May 2025.

"The Therapeutic Potential and Risks of Psilocybin and Psilocin for PTSD Treatment." Saving Grace Medical, 15 Aug. 2023, https://www.savinggracemedical.com/post/the-therapeutic-potential-and-risks-of-psilocybin-and-psilocin-for-ptsd-treatment. Accessed 10 May 2025.

"UCSF Psilocybin Clinical Trials for 2025 — San Francisco Bay Area." UCSF Clinical Trials, https://clinicaltrials.ucsf.edu/psilocybin. Accessed 10 May 2025.

"USF Health Explores Psychedelics for Treatment-Resistant Depression." University of South Florida Health, 7 Aug. 2024, https://www.usf.edu/health/news/2024/psilocybin-usfh-08072024.aspx. Accessed 10 May 2025.

Zhang, Liming, et al. "Psilocybin facilitates fear extinction in mice by promoting hippocampal neuroplasticity." Chinese Medical Journal, vol. 136, no. 24, 2023, pp. 2983-92.

‍